Horowitz J B, Kaye J, Conrad P J, Katz M E, Janeway C A
Proc Natl Acad Sci U S A. 1986 Mar;83(6):1886-90. doi: 10.1073/pnas.83.6.1886.
The growth of T lymphocytes is dependent on the T-cell growth factor interleukin 2 (IL-2), which causes T cells bearing high-affinity receptors for IL-2 to proliferate. Most cloned helper-T-cell lines can be shown to both produce and respond to IL-2; thus, growth of such cells is by an autocrine mechanism. We report that the failure of the cloned murine T-cell line D10.G4.1 to respond to its own IL-2 results from the secretion, by the same cells, of a potent inhibitor of the IL-2-driven T-cell proliferative response. This inhibition can be overcome by increasing the number of IL-2 receptors expressed by the target cell. In the cloned T-cell line producing the inhibitory substance, this increase in IL-2 receptors is driven by the monokine interleukin-1. We propose that this inhibitor of IL-2 responses may play a role in preventing "bystander" activation of T cells by IL-2 released in vivo and could be a potent pharmacologic agent.
T淋巴细胞的生长依赖于T细胞生长因子白细胞介素2(IL-2),IL-2可使带有高亲和力IL-2受体的T细胞增殖。大多数克隆的辅助性T细胞系既能产生IL-2又能对其作出反应;因此,这类细胞的生长是通过自分泌机制实现的。我们报告,克隆的小鼠T细胞系D10.G4.1不能对自身的IL-2作出反应,是因为同一细胞分泌了一种强效的IL-2驱动的T细胞增殖反应抑制剂。这种抑制作用可通过增加靶细胞表达的IL-2受体数量来克服。在产生抑制物质的克隆T细胞系中,IL-2受体数量的增加是由单核因子白细胞介素-1驱动的。我们提出,这种IL-2反应抑制剂可能在防止体内释放的IL-2对T细胞的“旁观者”激活中起作用,并且可能是一种强效的药物制剂。